Durvalumab outcomes for patients with PD-L1 positive and negative stage III unresectable non-small cell lung cancer treated at veterans health administration facilities

被引：0
|
作者：
Burton, Elizabeth M.
Moore, Amanda
Nooruddin, Zohra
Cotarla, Ion
Simmons, Daniel
Davis, Laura
Reveles, Kelly R.
Datta, Paromita
Souza, Gabriel Roman
Irabor, Omoruyi Credit
Franklin, Kathleen
Jones, Xavier
Frei, Christopher R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
[3] Univ Texas Hlth San Antonio, San Antonio, TX USA
[4] AstraZeneca, Gaithersburg, MD USA
[5] Univ Texas Austin, San Antonio, TX USA
[6] South Texas Vet Hlth Care Syst, San Antonio, TX USA
[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18793
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PD-L1 expression, EGFR mutations (EGFRm) and KRAS mutations (KRASm) in stage III unresectable non-small cell lung cancer (NSCLC) patients
    Cronin-Fenton, Deirdre
    Dalvi, Tapashi
    Hedgeman, Elizabeth
    Norgaard, Mette
    Pedersen, Lars
    Hansen, Hanh
    Fryzek, Jon
    Walker, Jill
    Mellemgaard, Anders
    Rasmussen, Torben R.
    Shire, Norah
    Rigas, James
    Potter, Danielle
    Hamilton-Dutoit, Stephen
    Sorensen, Henrik T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 384 - 385
  • [32] Prognostic significance of PD-L1 in stage II/III non-small cell lung cancer.
    Tural, Deniz
    Karaca, Mustafa
    Akar, Emre
    Okay, Damla
    Cil, Ibrahim
    Akyurek, Nalan
    Uner, Aytug
    Ozet, Ahmet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Retrospective analysis between PD-L1 expression and prognosis for stage III non-small cell lung cancer patients
    Tokito, Takaaki
    Azuma, Koichi
    Ishii, Hidenobu
    Yamada, Kazuhiko
    Hoshino, Tomoaki
    ANNALS OF ONCOLOGY, 2015, 26 : 97 - 97
  • [34] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy
    Oh, H. -J.
    Park, C. -K.
    Kim, Y. -C.
    Kim, Y. -H.
    Ahn, S. -J.
    Jeong, W. G.
    Lee, J. Y.
    Lee, J. C.
    Choi, C. M.
    Ji, W.
    Song, S. Y.
    Choi, J.
    Lee, S. Y.
    Kim, H.
    Lee, S. Y.
    Park, J.
    Yoon, S. H.
    Joo, J. H.
    Oh, I. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S294 - S295
  • [35] Real world experience of survival outcomes in consolidative durvalumab in unresectable stage III non-small cell lung cancer (NSCLC)
    Pringle, Nicole
    Fletcher, James
    Arneil, Melissa
    Xu, Wen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 47 - 48
  • [36] Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
    Pringle, N.
    Fletcher, J. A.
    Morton, C.
    Mullally, W. J.
    Arneil, M.
    O'Byrne, K.
    Xu, W.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S569 - S569
  • [37] Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
    Raez, Luis E.
    Arrieta, Oscar
    Chamorro, Diego F.
    Denisse Soberanis-Pina, Pamela
    Corrales, Luis
    Martin, Claudio
    Cuello, Mauricio
    Samtani, Suraj
    Recondo, Gonzalo
    Mas, Luis
    Zatarain-Barron, Zyanya Lucia
    Ruiz-Patino, Alejandro
    Esteban Garcia-Robledo, Juan
    Ordonez-Reyes, Camila
    Jaller, Elvira
    Dickson, Franco
    Rojas, Leonardo
    Rolfo, Christian
    Rosell, Rafael
    Cardona, Andres F.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] VACTOSERTIB AND DURVALUMAB AS SECOND OR LATER LINE TREATMENT FOR PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER: INTERIM RESULT
    Cho, Byoung Chul
    Lee, Ki Hyeong
    Han, Ji-Youn
    Shim, Byoung Yong
    Kim, Hye Ryun
    Pyo, Kyoung-Ho
    Kim, Jae-Hwan
    Xin, Chung-Feng
    Lee, Jin Kyung
    Ryu, Jiyeon
    Oh, Bitna
    Hwang, Sunjin
    Hahm, Ki Baik
    Kim, Seong-Jin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A222 - A222
  • [39] Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
    Kerr, Keith M.
    Nicolson, Marianne C.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (03) : 249 - 254
  • [40] Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
    Nhung Pham
    Quyet Do
    Thang Ta
    Dung Nguyen
    Dai Do
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
12345